Daniel Fb Wright1, Matthew P Doogue2,3, Murray L Barclay2,3, Peter T Chapman2,4, Nicholas B Cross2, John H Irvine2, Lisa K Stamp2,4. 1. School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. dan.wright@otago.ac.nz. 2. Department of Medicine, University of Otago, Christchurch, New Zealand. 3. Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand. 4. Department of Rheumatology Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand.
Abstract
PURPOSE: The aims of this study were to characterise the population pharmacokinetics of oxypurinol in patients receiving haemodialysis and to compare oxypurinol exposure in dialysis and non-dialysis patients. METHODS: Oxypurinol plasma concentrations from 6 gout people receiving haemodialysis and 19 people with gout not receiving dialysis were used to develop a population pharmacokinetic model in NONMEM. Deterministic simulations were used to predict the steady-state area under the oxypurinol plasma concentration time curve over 1 week (AUC7days). RESULTS: The pharmacokinetics of oxypurinol were best described by a one-compartment model with a separate parameter for dialytic clearance. Allopurinol 100 mg daily produced an AUC7days of 279 μmol/L h in dialysis patients, a value 50-75 % lower than the AUC7days predicted for patients with normal renal function taking 200 to 400 mg daily (427-855 μmol/L h). Dosing pre-dialysis resulted in about a 25-35 % reduction in exposure compared to post-dialysis. CONCLUSIONS: Oxypurinol is efficiently removed by dialysis. The population dialytic and total (non-dialytic) clearance of oxypurinol were found to be 8.23 and 1.23 L/h, standardised to a fat-free mass of 70 kg and creatinine clearance of 6 L/h, respectively. Our results suggest that if the combination of low-dose allopurinol and haemodialysis does not result in sustained urate lowering below treatment targets (serum urate ≤0.36 mmol/L), then allopurinol doses may be increased to optimise oxypurinol exposure.
PURPOSE: The aims of this study were to characterise the population pharmacokinetics of oxypurinol in patients receiving haemodialysis and to compare oxypurinol exposure in dialysis and non-dialysis patients. METHODS:Oxypurinol plasma concentrations from 6 goutpeople receiving haemodialysis and 19 people with gout not receiving dialysis were used to develop a population pharmacokinetic model in NONMEM. Deterministic simulations were used to predict the steady-state area under the oxypurinol plasma concentration time curve over 1 week (AUC7days). RESULTS: The pharmacokinetics of oxypurinol were best described by a one-compartment model with a separate parameter for dialytic clearance. Allopurinol 100 mg daily produced an AUC7days of 279 μmol/L h in dialysis patients, a value 50-75 % lower than the AUC7days predicted for patients with normal renal function taking 200 to 400 mg daily (427-855 μmol/L h). Dosing pre-dialysis resulted in about a 25-35 % reduction in exposure compared to post-dialysis. CONCLUSIONS:Oxypurinol is efficiently removed by dialysis. The population dialytic and total (non-dialytic) clearance of oxypurinol were found to be 8.23 and 1.23 L/h, standardised to a fat-free mass of 70 kg and creatinine clearance of 6 L/h, respectively. Our results suggest that if the combination of low-dose allopurinol and haemodialysis does not result in sustained urate lowering below treatment targets (serum urate ≤0.36 mmol/L), then allopurinol doses may be increased to optimise oxypurinol exposure.
Entities:
Keywords:
Dialysis; Gout; NONMEM; Oxypurinol; Population pharmacokinetics; Renal function
Authors: Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp Journal: Br J Clin Pharmacol Date: 2015-12-29 Impact factor: 4.335
Authors: Kelsey M Jordan; J Stewart Cameron; Michael Snaith; Weiya Zhang; Michael Doherty; Jonathan Seckl; Aroon Hingorani; Richard Jaques; George Nuki Journal: Rheumatology (Oxford) Date: 2007-05-23 Impact factor: 7.580
Authors: Lisa K Stamp; Puja P Khanna; Nicola Dalbeth; Maarten Boers; Walter P Maksymowych; H Ralph Schumacher; Michael A Becker; Patricia A MacDonald; N Lawrence Edwards; Jasvinder A Singh; Lee S Simon; Fiona M McQueen; Tuhina Neogi; Angelo L Gaffo; Vibeke Strand; William J Taylor Journal: J Rheumatol Date: 2011-07 Impact factor: 4.666
Authors: Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub Journal: Arthritis Care Res (Hoboken) Date: 2012-10 Impact factor: 4.794
Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: L K Stamp; M L Barclay; J L O'Donnell; M Zhang; J Drake; C Frampton; P T Chapman Journal: Clin Pharmacol Ther Date: 2011-07-27 Impact factor: 6.875
Authors: Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford Journal: Eur J Clin Pharmacol Date: 2013-03-10 Impact factor: 2.953
Authors: Diluk R W Kannangara; Garry G Graham; Daniel F B Wright; Sophie L Stocker; Ian Portek; Kevin D Pile; Murray L Barclay; Kenneth M Williams; Lisa K Stamp; Richard O Day Journal: Br J Clin Pharmacol Date: 2017-05-28 Impact factor: 4.335
Authors: Lisa K Stamp; Hamish Farquhar; Huai Leng Pisaniello; Ana B Vargas-Santos; Mark Fisher; David B Mount; Hyon K Choi; Robert Terkeltaub; Catherine L Hill; Angelo L Gaffo Journal: Nat Rev Rheumatol Date: 2021-07-30 Impact factor: 20.543